Shanghai Labway Clinical Laboratory Co., Ltd. (301060.SZ)
CNY 8.9
(-0.45%)
CNY 8.9
(-0.45%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 329.31 Million CNY | -80.55% |
| 2022 | 1.79 Billion CNY | 163.34% |
| 2021 | 679.89 Million CNY | 70.04% |
| 2020 | 399.83 Million CNY | 14.74% |
| 2019 | 348.46 Million CNY | 7.26% |
| 2018 | 324.88 Million CNY | 16.54% |
| 2017 | 278.77 Million CNY | 3.28% |
| 2016 | 269.92 Million CNY | 26.42% |
| 2015 | 213.51 Million CNY | 27.48% |
| 2014 | 167.49 Million CNY | -3.04% |
| 2013 | 172.73 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 95.1 Million CNY | -0.52% |
| 2024 Q3 | 72.43 Million CNY | -21.11% |
| 2024 Q1 | 95.6 Million CNY | 156.63% |
| 2023 Q2 | 95.43 Million CNY | -20.46% |
| 2023 Q3 | 95.61 Million CNY | 0.19% |
| 2023 FY | 348.28 Million CNY | -80.55% |
| 2023 Q4 | 37.25 Million CNY | -61.04% |
| 2023 Q1 | 119.98 Million CNY | -72.09% |
| 2022 Q2 | 566.86 Million CNY | 42.8% |
| 2022 Q1 | 396.95 Million CNY | 122.11% |
| 2022 FY | 1.79 Billion CNY | 163.34% |
| 2022 Q4 | 429.89 Million CNY | 8.37% |
| 2022 Q3 | 396.7 Million CNY | -30.02% |
| 2021 Q3 | 207.26 Million CNY | 35.32% |
| 2021 Q4 | 178.72 Million CNY | -13.77% |
| 2021 Q1 | 137.95 Million CNY | 27.91% |
| 2021 Q2 | 153.16 Million CNY | 11.02% |
| 2021 FY | 679.89 Million CNY | 70.04% |
| 2020 Q4 | 107.85 Million CNY | -84.52% |
| 2020 FY | 399.83 Million CNY | 14.74% |
| 2020 Q3 | 696.94 Million CNY | 9210.5% |
| 2020 Q2 | 7.48 Million CNY | -29.31% |
| 2020 Q1 | 10.58 Million CNY | -96.75% |
| 2019 FY | 348.46 Million CNY | 7.26% |
| 2019 Q4 | 325.49 Million CNY | 0.0% |
| 2018 FY | 324.88 Million CNY | 16.54% |
| 2017 Q1 | 76.36 Million CNY | 7.61% |
| 2017 Q2 | 76.36 Million CNY | 0.0% |
| 2017 FY | 278.77 Million CNY | 3.28% |
| 2016 Q3 | 70.96 Million CNY | 10.87% |
| 2016 Q4 | 70.96 Million CNY | 0.0% |
| 2016 FY | 269.92 Million CNY | 26.42% |
| 2016 Q1 | 64 Million CNY | -3.25% |
| 2016 Q2 | 64 Million CNY | 0.0% |
| 2015 FY | 213.51 Million CNY | 27.48% |
| 2015 Q1 | 40.6 Million CNY | 0.0% |
| 2015 Q3 | 66.15 Million CNY | 62.93% |
| 2015 Q4 | 66.15 Million CNY | 0.0% |
| 2015 Q2 | 40.6 Million CNY | 0.0% |
| 2014 FY | 167.49 Million CNY | -3.04% |
| 2013 FY | 172.73 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 4.15 Billion CNY | 92.069% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.72 Billion CNY | 87.904% |
| Dirui Industrial Co.,Ltd. | 669.29 Million CNY | 50.797% |
| Beijing Strong Biotechnologies, Inc. | 1.3 Billion CNY | 74.675% |
| Medicalsystem Biotechnology Co., Ltd. | 834.37 Million CNY | 60.532% |
| Maccura Biotechnology Co.Ltd | 1.51 Billion CNY | 78.214% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.72 Billion CNY | 80.904% |
| Guangdong Hybribio Biotech Co.,Ltd. | 662.35 Million CNY | 50.281% |
| BGI Genomics Co., Ltd. | 2.17 Billion CNY | 84.828% |
| Amoy Diagnostics Co., Ltd. | 871.54 Million CNY | 62.215% |